NSA administration inhibits the expression of mixed lineage kinase domain-like (MLKL) through the ubiquitination proteasome pathway and then greatly reduces infarct volume and improves neurological recovery after cerebral ischemia-reperfusion [24]. Here, MLKL is linked to Cerebral ischemia.